Genpact Limited (G)

Technology · Information Technology Services
$33.45 -0.21% on the day Market cap $6.2B 52-week range $26.85 to $48.64 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
-7% a year for 10 years

At a market value of $6.2B, Genpact Limited's free cash flow of $735M (fiscal 2025) would need to grow about -7% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Genpact Limited's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price-6.6% a year
Free cash flow, last 9 years12.1% a year
Revenue, same period7.9% a year
Price to free cash flow8.4x

Fundamental grade

C

Five factors scored 1 to 9 from G's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation7
Profitability6
Growth5
Financial health4
Cash efficiency7

Key numbers

P/E (trailing)11.2x
P/E (forward)20.8x
Price / free cash flow8.39x
EV / EBITDA7.47x
Price / sales1.17x
Price / book2.49x
Revenue growth+7.1%
Operating margin14.8%
Net margin11.1%
Return on equity22.4%
Dividend yield1.9%
Debt / equity1.08x

Results from SEC filings

Fiscal years, from Genpact Limited's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$4.0B$4.4B$4.5B$4.8B$5.1B
Net income$369M$353M$631M$514M$552M
Free cash flow$641M$393M$435M$533M$735M
EPS (diluted)$1.91$1.88$3.41$2.85$3.13
Operating margin12.7%11.5%14.1%14.7%14.8%

Where the revenue comes from

Revenue by segments, fiscal 2025.

High Tech and Manufacturing$2.0B39%
Consumer and Healthcare$1.7B34%
Financial Services$1.4B27%

Superinvestors who own G

From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Trimmed $233M0.08%Q2 2026
Richard Pzena
Pzena Investment Management
Added $91M0.27%Q2 2026
Joel Greenblatt
Gotham Asset Management
New position $22M0.05%Q2 2026
C.T. Fitzpatrick
Vulcan Value Partners
Trimmed $14M0.44%Q2 2026
Ed Wachenheim
Greenhaven Associates
Held $275,0000.00%Q2 2026

Insider buying

Open-market purchases by Genpact Limited's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of G in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when G trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Genpact Limited's stock price imply?

At a market value of $6.2B, Genpact Limited would need its free cash flow to grow about -7% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 12% a year.

Are Genpact Limited insiders buying the stock?

No open-market insider purchases of G in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Genpact Limited?

5 of the superinvestors Investingly tracks hold G in their latest 13F, including Cliff Asness, Richard Pzena, Joel Greenblatt.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.